1. Raethjen J, Deuschl G. Tremor. Curr Opin Neurol 2009;22:400-405.
2. Shibasaki H, Thompson PD. Milestones in myoclonus. Mov Disord 2011;26:1142-1148.
3. Ozelius LJ, Lubarr N, Bressman SB. Milestones in dystonia. Mov Disord 2011;26:1106-1126.
4. Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. Lancet Neurol 2006;5:589-602.
5. Elble R, Deuschl G. Milestones in tremor research. Mov Disord 2011;26:1096-1105.
6. Halliday G, Lees A, Stern M. Milestones in Parkinson's disease: clinical and pathologic features. Mov Disord 2011;26:1015-1021.
7. Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonisms. Mov Disord 2011;26:1083-1095.
8. Alty JE, Kempster PA. A practical guide to the differential diagnosis of tremor. Postgrad Med J 2011;87:623-629.
9. Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor Mov Disord 2010;25:534-541.
10. Lorenz D, Poremba C, Papengut F, Schreiber S, Deuschl G. The psychosocial burden of essential tremor in an outpatient- and a community-based cohort. Eur J Neurol 2011;18:972-979.
11. Dogu O, Louis ED, Sevim S, Kaleagasi H, Aral M. Clinical characteristics of essential tremor in Mersin, Turkey: a population-based door-to-door study. J Neurol 2005;252:570-574.
12. Louis ED, Barnes L, Albert SM, Cote L, Schneier FR, Pullman SL, Yu Q. Correlates of functional disability in essential tremor. Mov Disord 2001;16:914-920.
13. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 1998;13:Suppl 3. 2-23.
14. Fahn S, Tolosa E, Marin C. In: Jankovic J, Tolosa E, editor. Clinical rating scale for tremor. Parkinson's disease and movement disorders 1993;2nd ed. Baltimore: Williiams & Wilkins. 271-280.
15. Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson's disease. Lancet Neurol 2011;10:987-1001.
16. Oh M, Kim JS, Kim JY, Shin KH, Park SH, Kim HO, Moon DH, Oh SJ, Chung SJ, Lee CS. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med 2012;53:399-406.
17. Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet Neurol 2011;10:148-161.
18. Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB Jr, Okun MS, Sullivan KL, Weiner WJ. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2011;77:1752-1755.
19. Young RR, Growdon JH, Shahani BT. Beta-adrenergic mechanisms in action tremor. N Engl J Med 1975;293:950-953.
20. Koller WC, Pahwa PR, Lyons KE, Wilkinson SB. Deep brain stimulation of the Vim nucleus of the thalamus for the treatment of tremor. Neurology 2000;55:12 Suppl 6. S29-S33.
21. Schuurman PR, Bosch DA, Bossuyt PM, Bonsel GJ, van Someren EJ, de Bie RM, Merkus MP, Speelman JD. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 2000;342:461-468.
22. Rosenbaum F, Jankovic J. Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology 1988;38:522-527.
23. Soland VL, Bhatia KP, Volonte MA, Marsden CD. Focal task-specific tremors. Mov Disord 1996;11:665-670.
24. Hai C, Yu-ping W, Hua W, Ying S. Advances in primary writing tremor. Parkinsonism Relat Disord 2010;16:561-565.
25. Hallett M. Parkinson's disease tremor: pathophysiology. Parkinsonism Relat Disord 2012;18:Suppl 1. S85-S86.
26. Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:646-650.
27. Sung YH, Chung SJ, Kim SR, Lee MC. Factors predicting response to dopaminergic treatment for resting tremor of Parkinson's disease. Mov Disord 2008;23:137-140.
28. Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord 2011;26:2226-2231.
29. Shin HW, Kim MJ, Kim JS, Lee MC, Chung SJ. Levosulpiride-induced movement disorders. Mov Disord 2009;24:2249-2253.
30. Onofrj M, Thomas A, Paci C. Reversible parkinsonism induced by prolonged treatment with valproate. J Neurol 1998;245:794-796.
31. Armon C, Shin C, Miller P, Carwile S, Brown E, Edinger JD, Paul RG. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996;47:626-635.
32. Hauben M, Reich L. Valproate-induced parkinsonism: use of a newer pharmacovigilance tool to investigate the reporting of an unanticipated adverse event with an "old" drug. Mov Disord 2005;20:387.
33. Hallett M, Weiner WJ, Kompoliti K. Psychogenic movement disorders. Parkinsonism Relat Disord 2012;18:Suppl 1. S155-S157.
34. Schwingenschuh P, Katschnig P, Seiler S, Saifee TA, Aguirregomozcorta M, Cordivari C, Schmidt R, Rothwell JC, Bhatia KP, Edwards MJ. Moving toward "laboratory-supported" criteria for psychogenic tremor. Mov Disord 2011;26:2509-2515.
35. Deuschl G. Dystonic tremor. Rev Neurol (Paris) 2003;159(10 Pt 1):900-905.
36. Milanov I. Clinical and electromyographic examinations of patients with midbrain and cerebellar tremor. Electromyogr Clin Neurophysiol 2002;42:105-112.
37. Bain PG, Britton TC, Jenkins IH, Thompson PD, Rothwell JC, Thomas PK, Brooks DJ, Marsden CD. Tremor associated with benign IgM paraproteinaemic neuropathy. Brain 1996;119(Pt 3):789-799.
38. Seidel S, Kasprian G, Leutmezer F, Prayer D, Auff E. Disruption of nigrostriatal and cerebellothalamic pathways in dopamine responsive Holmes' tremor. J Neurol Neurosurg Psychiatry 2009;80:921-923.
39. Lorincz MT. Neurologic Wilson's disease. Ann N Y Acad Sci 2010;1184:173-187.
40. Gouider-Khouja N. Wilson's disease. Parkinsonism Relat Disord 2009;15:Suppl 3. S126-S129.